Immunovant announces five IND clearances for IMVT-1402 and plans to initiate registrational trials by March 2025

Immunovant, Inc.

2025-Q2 EPS reported -$1.34 vs consensus -$0.66 ▼ miss (-103.8%)

Five INDs cleared for IMVT-1402 across therapeutic areas including Graves' disease and rheumatoid arthritis.
Proof-of-concept data from batoclimab in Graves' disease showed 60% response rate at week 2; registrational trial for IMVT-1402 expected by year-end 2024.
Initiation of potentially registrational trial for IMVT-1402 in difficult-to-treat RA expected by March 31, 2025.
Batoclimab trials in MG and CIDP fully enrolled; data disclosures by March 31, 2025.
Appointed Melanie Gloria as COO effective Nov 18, 2024; net loss $109.1M for quarter ended Sept 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.